Quick Review,compounding

The landscape surrounding compounded semaglutide has undergone significant shifts, leaving many individuals questioning their ability to access these medications. While compounded semaglutide was once a more widely available alternative, recent regulatory changes, particularly following the resolution of the semaglutide shortage, have impacted its accessibility. This article aims to provide a comprehensive overview of the current situation, clarifying the status of compounded semaglutide and related GLP-1s based on the latest information from entities like the FDA.

The Shifting Tide: From Shortage to Restriction

For a period, the semaglutide shortage created a situation where compounding pharmacies played a crucial role in providing alternative formulations. During this time, compounded GLP-1s became a more accessible option for many patients seeking weight loss or management of type 2 diabetes. However, with the FDA officially declaring the semaglutide and tirzepatide shortages over, the regulatory framework for compounded semaglutide has changed dramatically.

As of April 2025, it has become illegal in many states to prescribe and compound GLP-1 medications that are essentially copies of FDA-approved drugs. This means that compounding pharmacies are generally no longer permitted to make and sell semaglutide injections that mimic the exact formulation of branded medications like Ozempic or Wegovy. The FDA has issued warnings and clarified policies, leading to compounded semaglutide products being phased out and, for almost everyone, the answer to "can I still get compounded semaglutide?" is now no. The FDA halts sales of compounded semaglutide for many common uses.

Understanding Compounded Medications and FDA Approval

It is crucial to understand that compounded semaglutide has historically not been FDA approved. Unlike branded medications such as Ozempic, which undergo rigorous review for safety, effectiveness, and quality, compounded "semaglutide" is NOT approved by the FDA and has not been subject to the same level of scrutiny. While compounding pharmacies can lawfully market medications by complying with specific sections of the Federal Food, Drug, and Cosmetic Act (e.g., section 503A or 503B), the current regulatory climate emphasizes the distinction between these formulations and their FDA-approved counterparts. Compounded drugs are not subject to the same FDA approval process.

There have been concerns raised about the safety and efficacy of some compounded versions, including reports of impure or ineffective products. The FDA's warning about compounded versions not being evaluated for safety and efficacy is concerning, although some argue that branded options can also be expensive.

Exceptions and Continued Availability

While the general availability of compounded semaglutide has been significantly restricted, there are still certain circumstances where compounding pharmacies can continue to legally produce tirzepatide or semaglutide with modifications that address unique patient needs. For example, if a patient has a specific allergy to an ingredient in the commercially available drug, a compounding pharmacy might be able to create a modified version. These are considered rare exceptions.

Furthermore, some telehealth platforms, such as Hims & Hers, have confirmed they will keep offering compounded semaglutide to eligible patients, potentially by utilizing different formulations or addressing specific patient requirements that fall within the updated regulations. However, the volume of compounded semaglutide being produced is now under stricter review.

What This Means for Patients

For individuals who were previously using compounded semaglutide, the current situation means that compounded semaglutide products are no longer permitted under current regulations for many. The semaglutide and tirzepatide shortages are officially over, and consequently, many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide. This necessitates a discussion with a healthcare provider to explore alternative treatment options.

It's important for patients to be aware that buy compounded semaglutide from online pharmacies may carry inherent risks due to the lack of FDA oversight. The compounded versions can't be made anymore in their previous widespread capacity.

The Future of Compounded GLP-1s

While the era of widespread compounded semaglutide may be drawing to a close for many, the concept of compounding itself is not disappearing. Compounding pharmacies will continue to play a vital role in creating customized medications for specific patient needs. The focus is shifting away from mass compounding of drugs that are essentially identical to FDA-approved medications and towards formulations that address unique medical requirements. The compounded GLP-1s are being phased out in their broad application, but the industry is adapting to the new regulatory environment. The FDA's removal of semaglutide from the drug shortage list marks a significant shift for compounding pharmacies, leading to a more regulated and restricted market for these specific compounds.